4D Advisors LLC Makes New $7.20 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

4D Advisors LLC bought a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 200,000 shares of the medical device company's stock, valued at approximately $7,204,000. Tandem Diabetes Care accounts for approximately 5.0% of 4D Advisors LLC's portfolio, making the stock its 5th largest position. 4D Advisors LLC owned about 0.30% of Tandem Diabetes Care at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. McIlrath & Eck LLC acquired a new position in Tandem Diabetes Care in the third quarter valued at $52,000. Franklin Resources Inc. grew its holdings in Tandem Diabetes Care by 95.6% in the 3rd quarter. Franklin Resources Inc. now owns 26,785 shares of the medical device company's stock valued at $1,136,000 after buying an additional 13,088 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after acquiring an additional 113,355 shares during the last quarter. Park Avenue Securities LLC lifted its holdings in shares of Tandem Diabetes Care by 34.5% during the 4th quarter. Park Avenue Securities LLC now owns 8,914 shares of the medical device company's stock worth $321,000 after acquiring an additional 2,286 shares during the period. Finally, LVW Advisors LLC boosted its position in shares of Tandem Diabetes Care by 13.8% in the fourth quarter. LVW Advisors LLC now owns 7,798 shares of the medical device company's stock worth $281,000 after acquiring an additional 944 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded up $0.82 during trading on Wednesday, reaching $22.14. 347,191 shares of the company's stock traded hands, compared to its average volume of 1,497,217. The stock has a market capitalization of $1.47 billion, a P/E ratio of -11.45 and a beta of 1.47. The company has a 50 day moving average of $18.55 and a 200-day moving average of $28.38. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. During the same quarter in the previous year, the business posted ($0.65) earnings per share. The business's quarterly revenue was up 22.3% compared to the same quarter last year. On average, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on TNDM. Piper Sandler cut their price objective on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Wells Fargo & Company cut their price objective on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $35.00 to $25.00 in a research note on Friday, February 28th. Mizuho began coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price target on the stock. Finally, Barclays lowered their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.81.

Insider Activity

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.90% of the company's stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.